Difference between revisions of "Tivozanib (Fotivda)"
Jump to navigation
Jump to search
m |
|||
| Line 9: | Line 9: | ||
*[http://www.uptodate.com/contents/tivozanib-patient-drug-information Tivozanib (Fotivda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tivozanib-patient-drug-information Tivozanib (Fotivda) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/tivozanib-patient-drug-information Tivozanib (Fotivda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tivozanib-patient-drug-information Tivozanib (Fotivda) patient drug information (UpToDate)]</ref> | ||
| − | ==History of changes in FDA | + | ==History of changes in FDA indication== |
*3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | *3/10/2021: Approved for adult patients with relapsed or refractory advanced [[renal cell carcinoma|renal cell carcinoma (RCC)]] following two or more prior systemic therapies. ''(Based on TIVO-3)'' | ||
Revision as of 11:33, 18 June 2022
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death.[1][2][3]
Diseases for which it is established (work in progress)
Patient drug information
History of changes in FDA indication
- 3/10/2021: Approved for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. (Based on TIVO-3)
Also known as
- Code name: AV-951
- Brand name: Fotivda